TRAIL-coated leukocytes that prevent the bloodborne metastasis of prostate cancer

Global cancer statistics, 2012

Lindsey A. Torre, Freddie Bray, Rebecca L. Siegel et al. · CA A Cancer Journal for Clinicians · 2015 · 27.4K citations · Full text

Medicine, Oncology, Cancer Epidemiology +16

Phase I Dose-Escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients With Advanced Cancer

Roy S. Herbst, S. Gail Eckhardt, Razelle Kurzrock et al. · Journal of Clinical Oncology · 2010 · 440 citations

Life Sciences, Oncology, Pharmacology +17

Phase I Pharmacokinetic and Biologic Correlative Study of Mapatumumab, a Fully Human Monoclonal Antibody With Agonist Activity to Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Receptor-1

Anthony W. Tolcher, Monica Mita, Neal J. Meropol et al. · Journal of Clinical Oncology · 2007 · 311 citations · Full text

Medicine, Oncology, Pharmacology +17

The mTOR kinase inhibitor rapamycin decreases iNOS mRNA stability in astrocytes

Lucia Lisi, Pierluigi Navarra, Douglas L. Feinstein et al. · Journal of Neuroinflammation · 2011 · 235 citations · Full text

Life Sciences, Neuroscience, Pharmacology +15

TRAIL-coated leukocytes that kill cancer cells in the circulation

Michael J. Mitchell, Elizabeth Wayne, Kuldeepsinh Rana et al. · Proceedings of the National Academy of Sciences · 2014 · 214 citations · Full text

Life Sciences, Immunology, Oncology +17